Effects of tumor type on outcomes in patients with large vessel occlusion stroke and cancer

Shalabi, Fatma; Aladdin, Shorooq; Molad, Jeremy; Itsekzon-Hayosh, Z.; Sacagiu, Tzvika; Honig, Asaf; Halevi, Hen; Orion, David; Gomori, John M.; Cohen, José E.; Leker, Ronen R.

doi:10.1016/j.jstrokecerebrovasdis.2023.107288

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there may be a selection bias (patients who qualified for causative stroke treatment may have been in a generally better condition), the result of this study may add to the results of the previous ones, encouraging use of reperfusion therapies (especially MT, as having fewer contraindications) in patients even with advanced systemic cancer disease [ 42 ]. What is also interesting, Shalabi et al found that efficacy of MT in CP was not dependent on the cancer type [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Long-term outcomes of mechanical thrombectomy in acute ischaemic stroke patients with concomitant malignancy

Włodarczyk,

Wrona,

Homa

et al. 2024

pwki

View full text Add to dashboard Cite

Introduction Patients with cancer (CP) need a different approach to acute ischaemic stroke (AIS) treatment as intravenous thrombolysis (IVT) may be contraindicated. Mechanical thrombectomy (MT) is a treatment of choice for otherwise eligible patients, although the literature on its long-term outcomes in CP is limited. Aim Assessing outcomes of MT-treated AIS patients with concomitant malignancy in a year-long follow-up. Material and methods The study included 593 MT-treated AIS patients admitted in 2019–2021. The group was divided into CP (defined as a diagnosis of malignancy and undergoing/qualified for cancer treatment within previous 5 years) and a control group. The profile of cardiovascular risk factors, stroke severity and discharge, 90-day and 365-day outcomes were compared between the groups. Results CP and controls had a similar profile of cardiovascular risk factors and comparable stroke severity. CP were less frequently treated with IVT (25.7% vs. 59.1%, p < 0.001). There were no differences between the groups in the successful reperfusion rate and occurrence of haemorrhagic complications. Discharge and 90-day outcomes were similar. CP had higher 365-day mortality (48.6% vs. 29.9%, p = 0.024) but the percentage of patients achieving good functional outcome in a year-long observation was comparable. Conclusions Treatment with MT seems beneficial for AIS patients with concomitant malignancy both in short- and long-term observation.

show abstract

Section: Discussionmentioning

confidence: 99%